Maprium and Vitaccess formed a partnership to enable biopharma companies to derive greater value and increased impact from early/managed access programs

Maprium enables pharmaceutical and biotech companies to design, manage and govern Managed Access Programs globally. As innovation accelerates, access remains the primary bottleneck for patients. Managed Access — also known as Expanded Access, Compassionate Use, Named Patient and Post-Trial Access — is now a strategic, regulatory and ethical requirement. Yet many organisations still rely on fragmented tools, manual processes and vendor-owned systems to manage complex global programmes. Maprium provides the digital infrastructure for Managed Access. Our platform embeds regulatory, medical and safety requirements into configurable, country-aware workflows, giving sponsors full visibility, control and auditability across programmes and geographies. Unlike service-led models, Maprium is sponsor-owned and vendor-agnostic, enabling companies to retain ownership of their data, governance and long-term access strategy while working with preferred partners. Built specifically for regulated life sciences environments, Maprium supports equitable, compliant and scalable access to medicines — without compromising control or data integrity. Built for compliance. Built for scale. Built for pharma.